Press Releases

BeiGene Announces Clinical Data on Tislelizumab and Zanubrutinib to be Presented at the 24th Congress of the European Hematology Association

May 16, 2019 at 9:00 AM EDT

CAMBRIDGE, Mass. and BEIJING, China, May 16, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced data presentations on its investigational anti-PD-1 antibody tislelizumab and its investigational BTK inhibitor zanubrutinib from four posters at the 24th Congress of the European Hematology Association (EHA), taking place June 13-16, 2019 in Amsterdam.

Poster Presentations:

Title: Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: updated follow-up efficacy and safety results from a Phase 2 study
Abstract Code: PF469
Session Title: Hodgkin lymphoma – Clinical
Date: Friday, June 14
Time: 17:30 – 19:00 (CEST)
Lead Author: Yuqin Song, M.D., Ph.D.


Title: Major responses in MYD88 wildtype (MYD88WT) Waldenström Macroglobulinemia (WM) patients treated with Bruton Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111)
Abstract Code: PF487
Session Title: Indolent and mantle-cell non-Hodgkin lymphoma – Clinical
Date: Friday, June 14
Time: 17:30 – 19:00 (CEST)
Lead Author: Meletios A. Dimopoulos, M.D.


Title: Updated safety and efficacy data in a Phase 1/2 trial of patients with Waldenström Macroglobulinaemia (WM) treated with the Bruton Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111)
Abstract Code: PF481
Session Title: Indolent and mantle-cell non-Hodgkin lymphoma – Clinical
Date: Friday, June 14
Time: 17:30 – 19:00 (CEST)
Lead Author: Judith Trotman, MBChB, FRACP, FRCPA


Title: Pooled analysis of safety data from monotherapy studies of the Bruton Tyrosine Kinase (BTK) inhibitor, zanubrutinib (BGB-3111), in B-cell malignancies
Abstract Code: PS1159
Session Title: Chronic lymphocytic leukemia and related disorders – Clinical
Date: Saturday, June 15
Time: 17:30 – 19:00 (CEST)
Lead Author: Constantine S. Tam, M.D.

About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,400 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin-bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.i

Investor Contact                         Media Contact
Craig West                                    Liza Heapes
+1 857-302-5189                          +1 857-302-5663
ir@beigene.com                           media@beigene.com


i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation

BEI_ONC_4C_FlatLogo_Horizontal.jpg

Source: BeiGene, LTD.